HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export business. We have established a "1+2+3+4=1" service system and can supply D-chiro-Inositol sourced from multiple well-known original manufacturers. As a foreign trader with independent R&D capabilities, HiSiaddi has collaborated with factories on technology conversion and accurately captured market demands, repeatedly proposing formula optimization solutions and application improvement suggestions for D-chiro-Inositol. Below is a case of HiSiaddi’s formula optimization consulting service for D-chiro-Inositol.
Contact HiSiaddi customer service for more formula optimization consulting services.
The purchaser is FEMWELL, a leading mid-to-high-end nutrition group based in Canada. Its products are sold nationwide at Shoppers Drug Mart pharmacy chains and private obstetrics and gynecology clinics, focusing on PCOS-regulating compound capsules and solid instant powder drinks. All raw materials comply with Canada HPB, USP, cGMP and Clean Label regulations. The brand previously sourced D-chiro-Inositol (DCI) from European and American manufacturers with an annual procurement volume of 36 tons. To cut raw material costs, the client independently purchased 14 tons of national standard DCI off-the-shelf materials from two domestic factories, which triggered full-line production shutdowns upon arrival. Nearly 2 tons of pre-blended semi-finished products faced scrapping, delaying the new product launch plan. The client’s mature fixed formulas are as follows:
1. Hard Capsule Formula: 18% DCI + 72% Myo-Inositol + folic acid + plant extracts + direct compression excipients, produced on fully automatic high-speed capsule filling lines.
2. Instant Powder Formula: 6% DCI + prebiotics + fruit and vegetable powder, produced on single-serve stick pack filling lines.
Four typical technical failures emerged after production startup. Manufacturers could only provide COA for product content without downstream formulation R&D capabilities, and repeated adjustments to feeding ratios failed to resolve issues. The client commissioned HiSiaddi, equipped with dual R&D teams covering raw material processes and formulation development, to conduct full-range fault tracing, raw material improvement and formula & process optimization. Detailed failures:
1. Capsule filling blockages and excessive fill weight deviation: Fine powder proportion exceeded 42%, severe powder static electricity, repose angle of 48.5°, frequent arching and bridging in silos, capsule fill weight RSD >7% (failing Canada Pharmacopoeia internal control standard ≤3%), requiring machine shutdown and cleaning every 20 minutes during high-speed filling.
2. Capsule shell moisture softening and content caking during long-term storage: After 30 days of accelerated ambient temperature testing, white crystalline adhesion formed on capsule inner walls, failing shelf stability inspections required for pharmacy warehouse admission.
3. Solid powder moisture absorption and agglomeration, with turbid precipitates upon reconstitution: Trace residual alcohol solvents and excessive free impurities in raw materials cause severe moisture absorption after blending with prebiotics, generating insoluble flocs upon warm water reconstitution, failing sensory and physicochemical standards.
4. Excessive efficacy decline under accelerated stability testing: After storage at 40°C, DCI chiral isomers gradually increased, reducing product bioavailability by 21%, violating efficacy filing standards for end-market retail.
HiSiaddi collected the client’s in-use DCI raw materials, semi-finished products and supporting excipients, and collaborated with a CNAS pharmaceutical testing laboratory to conduct full testing against Canadian access standards. By comparing control parameters of the client’s original imported DCI, we identified the root causes of failures:
1. Chaotic crystal form and uncontrolled particle size: Manufacturers adopt D-pinitol acid hydrolysis with crude crystallization without classification, mixing acicular fine powder and irregular coarse crystals with particle sizes ranging from 20–300 mesh. Excessive fine powder triggers static electricity and collapses powder flowability.
2. Excessive moisture and residual solvents: Raw material moisture content reached 0.42% (client internal control upper limit: 0.18%), with methanol + ethanol residues at 36ppm. Slow migration of small molecule residues leads to capsule shell dampening and powder moisture absorption & crystal precipitation.
3. Elevated chiral impurities and isomers: Hydrolysis processes cannot deeply remove trace isomer impurities, with total impurities at 0.68%. Impurities accumulate over long-term storage, directly undermining product stability and absorption efficiency.
4. Excessive trace inorganic impurities: Trace calcium and magnesium inorganic salts introduced during production form complexes with folic acid and plant polyphenols in the formula, generating flocculent precipitates when the powder is reconstituted.
The complete formula was designed around imported DCI with spherical high-purity particles. The original anti-caking aids and moisture-proof carrier dosages matched the physical properties of imported raw materials but failed to adapt to domestic raw materials with high fine powder content and strong moisture absorption, leading to severely unbalanced moisture-proof systems and powder modification excipient ratios.
1. Crystallization Process Upgrade: Replace one-time rapid cooling crystallization with segmented recrystallization at controlled cooling rates, transforming chaotic acicular crystals into short columnar regular particles. Air flow classification screening equipment was installed to lock particle sizes at 90–130 mesh, reducing fine powder proportion to below 7% and lowering repose angle to 35°, completely improving powder flowability.
2. Deep Purification & Impurity Removal: Add cation-anion exchange resin impurity removal sections to eliminate heavy metals and chiral isomer impurities. Segmented high-vacuum low-temperature drying was adopted to control moisture at 0.14%, total organic solvent residues ≤18ppm and total impurities ≤0.17%, meeting USP chiral purity standards.
3. D-Class Clean Closed Screening: Crushing and packaging conducted in fully enclosed clean workshops to avoid additional fine powder generated during transit. Exclusive grade DCI-FEM01 was finalized, with 5kg modified samples air-shipped to the client’s Canadian laboratory for verification.
① Formula Fine-Tuning: Reduce DCI feeding proportion from 18% to 16.2%, add a composite anti-static flow aid system of 0.5% silicon dioxide + 0.7% magnesium stearate, slightly increase microcrystalline cellulose ratio to improve powder mixing uniformity and flowability. ② Production Control Optimization: Lock filling workshop ambient humidity at 43%–50%, reduce silo stirring speed, and pre-mix raw materials at low temperatures before feeding to eliminate static blockages.
① Formula Improvement: Add 1.3% modified maltodextrin moisture-proof coating carrier to wrap DCI powder via dry pre-coating technology for water vapor isolation; adjust fruit and vegetable powder feeding ratios to avoid inorganic salt complex precipitates. ② Filling Optimization: Adopt low oxygen permeability aluminum film stick packs for finished products and dehumidify filling workshops to eliminate storage agglomeration.
1. Full Compliance of Pilot Mass Production: The client conducted small-batch production of 600kg using modified DCI and optimized formulas. Capsule filling ran continuously for 8 hours without blockages, complying with fill weight deviation standards. Capsules showed no softening or crystal precipitation after 90 days of ambient storage; powder remained dry and lump-free after 60 days of storage with clear reconstitution without precipitates. Efficacy decay rate under accelerated testing dropped to 3.8%, restoring full operation of both production lines.
2. Revitalize Existing 14 Tons of Standard DCI Inventory to Avoid Massive Client Losses: HiSiaddi provided a blending application scheme for unmodified old raw materials in stock: blend old materials and new modified materials at a ratio of 3:7 for feeding, following all optimized formula parameters to fully consume the entire inventory over 5 months, eliminating high ocean freight and port detention fees for full-container returns.
3. Signing of Annual Procurement Framework Agreement: The comprehensive procurement cost of modified domestic DCI decreased by 29.2% compared with original imported materials. The client finalized a 36-ton annual long-term contract with quarterly batch deliveries, specifying fixed customized indicators for grade DCI-FEM01 and mandatory bioconversion processes, prohibiting future purchases of standard hydrolysis-grade materials. All raw material selection and pre-formula testing for the client’s new compound inositol effervescent powder product line were entrusted to HiSiaddi’s technical team.
HiSiaddi established exclusive product files for the client, archiving batch raw material COAs and process documents. We track real-time updates to Canada HPB regulations and USP standard revisions to synchronize internal raw material control standards in advance, providing free gradient samples and formula references for new product R&D.
1. Common Industry Pain Points: Most domestic DCI manufacturers mass-produce goods via acid hydrolysis, only meeting national standard content requirements without controlling formulation-critical indicators such as crystal form, particle size, residual solvents and trace isomers. Lacking downstream formulation application R&D capabilities, their off-the-shelf materials only fit low-end bulk food applications and cannot directly match formulas of mid-to-high-end North American and Canadian pharmacy nutraceuticals.
2. Mid-to-High-End Overseas Procurement Logic: Nutraceuticals sold at Canadian pharmacies are subject to dual supervision by local food regulatory authorities and chain retailers. Raw material physical properties, formula compatibility, shelf stability and in-vivo absorption rates are all tied to product filings; minor deviations in raw material indicators can trigger full-line shutdowns and finished product scrapping.
3. HiSiaddi Core Competitiveness: Covering the full industrial chain from upstream raw material process improvement to downstream formulation optimization, breaking the traditional foreign trade model of pure supply resale. Drawing on R&D reserves for amino acid and inositol raw materials plus formulation technology, we resolve the two-way information barrier between manufacturers lacking end-formulation expertise and clients unfamiliar with raw material production processes, securing stable long-term repeat orders through full-chain technical services.
Contact HiSiaddi customer service for more formula optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
